Updated Lists Of Stocks Topping Our Ranking Model
Background It has been a year since we first introduced our factor-based quality ranking model (see “13 Stocks That Top My Factor-Based Value Investing Ranking […]
GILD
January 2019 Stock Considerations | Seeking Alpha
With a new year and a new month upon us, it is time, once again, for me to outline my potential stock picks for my […]
Marker Therapeutics Exits ASH An Optimist. Should That Be Enough For You? – Marker Therapeutics Inc (NASDAQ:MRKR)
Please note that I am affiliated with Avisol Capital Partners and their Total Pharma Tracker service. They have also covered the companies in this article […]
Portfolio Update: Stocks Getting Slammed As Dividends Shine Bright
My investment career is still very short (roughly 2.5 years) and as such the volatility we are now experiencing daily in the markets is certainly […]
How To Retire At 62 With Just Half A Million
In the previous article that we wrote on our hypothetical couple – John and Lisa – we tried to demonstrate how they could retire in […]
Celgene Doesn’t Want To Be Left Out, Posts Promising JCAR017 Data – Celgene Corporation (NASDAQ:CELG)
Recently, Celgene (CELG) announced preliminary data from its study treating patients with relapsed/refractory (r/r) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). The data […]
Viking Therapeutics Won’t Live Up To The Hype – Viking Therapeutics (NASDAQ:VKTX)
NASH – an introduction Fatty deposits and mild fibrosis in non-alcoholic fatty liver disease. Source NASH – short for non-alcoholic steatohepatitis – has been a […]
Bloomberg 2019 Watchlist: 50 Dividend Dogs Show Target Gains And Losses
Bloomberg Selections At year end, Bloomberg Business Week features a list of 50 to 100 news and noteworthy stocks for the upcoming year. The 2019 […]
Week In Review: Alphamab Closes $100 Million Series A For Oncology Candidates
Deals and Financings Alphamab Oncology, a clinical-stage Suzhou biopharma, completed a Series A funding with over $100 million in capital. Earlier this year, Alphamab Oncology […]
CAR-T Cells In The Real World – Gilead Sciences, Inc. (NASDAQ:GILD)
Real world experience with CAR-T cells for lymphoma will be discussed at the ASH meetings beginning on December 1, 2018. These discussions will be important […]